HRT and hyperparathyroidism

NEW YORK, July 26 (Praxis Press) Hormone replacement therapy (HRT) is a possible alternative to parathyroidectomy in the treatment of hyperparathyroidism, but the efficacy of HRT in the long-term treatment of chronic stable primary hyperparathyroidism is unclear. To assess this, Orr-Walker and colleagues performed a randomized, placebo-controlled trial of 23 postmenopausal women with primary hyperparathyroidism over the course of 2 to 4 years. Of the 23 women, 11 received HRT and 12 received pla

July 31, 2000

NEW YORK, July 26 (Praxis Press) Hormone replacement therapy (HRT) is a possible alternative to parathyroidectomy in the treatment of hyperparathyroidism, but the efficacy of HRT in the long-term treatment of chronic stable primary hyperparathyroidism is unclear. To assess this, Orr-Walker and colleagues performed a randomized, placebo-controlled trial of 23 postmenopausal women with primary hyperparathyroidism over the course of 2 to 4 years. Of the 23 women, 11 received HRT and 12 received placebo. They measured bone mineral density at si6-month intervals using dual-energy x-ray absorptiometry in these women and in 50 normocalcemic age-matched control subjects. Changes in bone mineral density were more positive in those taking HRT than placebo, with the between-group differences at 4 years being 4.6% in the total body, 7.5% in the lumbar spine, 7.4% in the femoral neck, 8.2% in the femoral trochanter, 6.8% in the legs, and 7.0% in the forearm. HRT may be useful in the long-term management of osteopenia in postmenopausal women with primary hyperparathyroidism.

Popular Now

  1. Can Young Stem Cells Make Older People Stronger?
  2. Thousands of Mutations Accumulate in the Human Brain Over a Lifetime
  3. CRISPR to Debut in Clinical Trials
  4. Two Dozen House Republicans Do an About-Face on Tuition Tax